GlaxoSmithKline PLC ADR is a drug manufacturers - general business with stocks listed in the US. GlaxoSmithKline shares (GSK) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$41.61 – an increase of 0.9% over the previous week. Here's how to invest if you're based in Australia.
GlaxoSmithKline's shares were split on a 1226:1000 basis on 21 July 2022. So if you had owned 1000 shares the day before the split, the next day you would own 1226 shares. This wouldn't directly have changed the overall worth of your GlaxoSmithKline shares – just the quantity. However, indirectly, the new 18.4% lower share price could have impacted the market appetite for GlaxoSmithKline shares which in turn could have impacted GlaxoSmithKline's share price.
| 52-week range | US$32.3451 - US$43.84 |
|---|---|
| 50-day moving average | US$41.8292 |
| 200-day moving average | US$37.875 |
| Target price | US$45.39 |
| PE ratio | 13.8041 |
| Dividend yield | US$0.58 (3.59%) |
| Earnings per share (TTM) | US$2.96 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $41.61
| 1 week (2024-04-24) | 1.84% |
|---|---|
| 1 month (2024-04-01) | -1.91% |
| 3 months (2024-02-01) | 2.41% |
| 6 months (2023-11-01) | 20.33% |
| 1 year (2023-05-01) | 14.94% |
|---|---|
| 2 years (2022-04-29) | 12.66% |
| 3 years (2021-04-30) | 36.62% |
| 5 years (2019-05-01) | 26.24% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing GlaxoSmithKline stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GlaxoSmithKline's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GlaxoSmithKline's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, GlaxoSmithKline shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0866. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
GlaxoSmithKline's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$10.3 billion (£8.3 billion).
The EBITDA is a measure of a GlaxoSmithKline's overall financial performance and is widely used to measure stock profitability.
Over the last 12 months, GlaxoSmithKline's shares have ranged in value from as little as US$32.3451 up to US$43.84. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while GlaxoSmithKline's is 0.268. This would suggest that GlaxoSmithKline's shares are less volatile than average (for this exchange).
| Revenue TTM | US$30.3 billion |
|---|---|
| Operating margin TTM | 20.36% |
| Gross profit TTM | US$19.9 billion |
| Return on assets TTM | 8.81% |
| Return on equity TTM | 46.38% |
| Profit margin | 16.25% |
| Book value | 3.29 |
| Market capitalisation | US$83.5 billion |
TTM: trailing 12 months
Dividend payout ratio: 37.56% of net profits
Recently GlaxoSmithKline has paid out, on average, around 37.56% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.59% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), GlaxoSmithKline shareholders could enjoy a 3.59% return on their shares, in the form of dividend payments. In GlaxoSmithKline's case, that would currently equate to about $0.58 per share.
While GlaxoSmithKline's payout ratio might seem fairly standard, it's worth remembering that GlaxoSmithKline may be investing much of the rest of its net profits in future growth.
GlaxoSmithKline's most recent dividend payout was on 10 April 2024. The latest dividend was paid out to all shareholders who bought their shares by 21 February 2024 (the "ex-dividend date").
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Everything we know about the Sun Silver IPO, plus information on how to buy in.
Everything we know about the Tasmea Limited IPO, plus information on how to buy in.
Steps to owning and managing Far Northern Resources shares.
Commodity ETFs can be used to hedge against inflation. Here's what they do, why they should be on your watchlist and how they can help your portfolio.
Looking for the best performing stocks in Australia? We update this list weekly.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Trade ASX stocks and ETFs with a $2 brokerage fee and a low minimum investment of just $10.
These ETFs have the lowest fees on the market, but does that make them the best?
You've heard of CommSec but how does it stack up to the likes of IG, CMC Invest and other players in the market?
Westpac Share Trading allows you to take control of your investments. Find out if its right for you.